Mobile Health Rehabilitation for Heart Disease
(RESILIENT Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byJohn Dodson, MD

Age: 65+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: NYU Langone Health

No Placebo Group

Trial Summary

What is the purpose of this trial?RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint. This study aims to evaluate whether mHealth-CR improves functional capacity in older adults (age ≥65) with IHD compared with standard traditional cardiac rehabilitation care. A total of 400 eligible patients will be randomized in 3:1 manner to mHealth-CR versus usual care for assessment of primary endpoint. Enrollment will occur over approximately 42 months with an expected minimum of 3 months follow-up per participant.

Eligibility Criteria

This trial is for older adults aged 65 or above who have been hospitalized for ischemic heart disease (like a heart attack, stent placement, or bypass surgery) recently. They must be able to walk, give consent themselves, and use mobile health technology in English or Spanish. People with severe movement disorders, very short life expectancy, severe cognitive issues, certain recent surgeries or conditions that limit walking are not eligible.

Inclusion Criteria

I can follow study instructions and perform tasks like a 6-minute walk test.

I am 65 years old or older.

I am currently in the hospital or was hospitalized in the last 2 weeks for a heart attack or heart surgery.

+1 more

Exclusion Criteria

You have a left ventricular assist device.

The doctors think there are other safety concerns or you might not follow the study rules.

I have significant memory or thinking problems.

+12 more

Participant Groups

The RESILIENT study tests if a mobile health cardiac rehab program (mHealth-CR) can improve the physical function of older adults after hospitalization due to heart disease better than standard care. Participants will either receive mHealth-CR or usual care in a ratio of 3:1 by random selection.

2Treatment groups

Experimental Treatment

Active Control

Group I: mHealth-CRExperimental Treatment1 Intervention

Group II: Usual CareActive Control1 Intervention